Clinical trials
Pancreatic Diseases trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
16 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 1 |
| 2009 | 3 |
| 2011 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2020 | 1 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 9 |
| Recruiting | 2 |
| Terminated | 2 |
| Active, not recruiting | 1 |
| Unknown status | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Assistance Publique - Hôpitaux de Paris | 2 |
| IHU Strasbourg | 2 |
| Vertex Pharmaceuticals Incorporated | 2 |
| Astellas Pharma Inc | 1 |
| Celgene | 1 |
| Centre Hospitalier Universitaire de Nice | 1 |
| Centre Hospitalier Universitaire, Amiens | 1 |
| Hospices Civils de Lyon | 1 |
| Nantes University Hospital | 1 |
| Rezolute | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pancreatic Diseases | 16 |
| Digestive System Diseases | 6 |
| Pancreatic Neoplasms | 6 |
| Adenocarcinoma | 3 |
| Cystic Fibrosis | 3 |
| Digestive System Neoplasms | 3 |
| Endocrine Gland Neoplasms | 3 |
| Endocrine System Diseases | 3 |
| Genetic Diseases, Inborn | 3 |
| Lung Diseases | 3 |
Trials
Showing 76 to 16 of 16. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.